Related Experiment Video
Updated: Jul 6, 2026
10:17
An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
Published on: November 3, 2010
A study on Chinese phenylalanine hydroxylase gene restriction site polymorphism
Scientia Sinica. Series B, Chemical, Biological, Agricultural, Medical & Earth Sciences
|December 1, 1988
Summary
This study analyzed restriction fragment length polymorphisms (RFLPs) in the phenylalanine hydroxylase (PAH) gene of Chinese patients with phenylketonuria (PKU). The findings enable prenatal diagnosis of PKU in the Chinese population.
Area of Science:
- Genetics
- Molecular Biology
- Medical Research
Background:
- Phenylketonuria (PKU) is a genetic disorder.
- Accurate genetic analysis is crucial for understanding PKU.
- The phenylalanine hydroxylase (PAH) gene is implicated in PKU.
Purpose of the Study:
- To analyze restriction fragment length polymorphisms (RFLPs) in the PAH gene of Chinese individuals.
- To establish RFLP frequencies in normal and phenylketonuric Chinese populations.
- To assess the utility of RFLPs for prenatal diagnosis of PKU in China.
Main Methods:
- Human PAH cDNA was used as a hybridization probe.
- Eight specific RFLPs (BglII, EcoRI, EcoRV, HindIII, MspIa, MspIb, PvuIIa, PvuIIb) were analyzed.
- RFLP analysis was performed on DNA from 80 normal and 28 PKU Chinese patients.
Main Results:
- Frequencies of eight RFLPs in normal Chinese and PKU patients were determined.
- Significant differences in RFLP frequencies were observed compared to Caucasian populations.
- Specific RFLP patterns were identified in the Chinese population.
Conclusions:
- The established RFLP frequencies provide a genetic profile for the Chinese population.
- Detected RFLPs in the PAH gene are valuable for PKU genetic studies.
- This research facilitates the prenatal diagnosis of PKU in China.
More Related Videos
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...